Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD

Detect and Profile Multiple Myeloma Measurable Residual Disease (MRD )Prognostics for Monitoring Post-transplant Multiple Myeloma (MM) Patients Receiving Maintenance Therapy.

The purpose :

Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.

Inclusion Criteria:

• Confirmed MM diagnosis
• Transplant eligible patients in a first remission
• Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)
• Availability of deidentified patient's demographic and clinical follow up data
• Receiving standard of care treatment
• Able to provide informed consent

Exclusion Criteria:

• Failure to meet inclusion criteria